VivoSim Labs, Inc. Operating Lease, Payments
VivoSim Labs, Inc. (VIVS) reported Operating Lease, Payments of $138.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-12
- VivoSim Labs, Inc. operating lease, payments for the quarter ending 2026-06-30 was $138.00K, a 2.99% increase year-over-year.
- VivoSim Labs, Inc. operating lease, payments for the quarter ending 2026-03-31 was $137.00K, a 1.48% increase year-over-year.
- VivoSim Labs, Inc. operating lease, payments for the quarter ending 2025-12-31 was $135.00K, a 4.65% increase year-over-year.
- VivoSim Labs, Inc. operating lease, payments for the quarter ending 2025-09-30 was $134.00K, a 3.08% increase year-over-year.
- VivoSim Labs, Inc. operating lease, payments for fiscal 2026 was $539.00K, a 2.86% increase from fiscal 2025.
- VivoSim Labs, Inc. operating lease, payments for fiscal 2025 was $524.00K, a 2.95% increase from fiscal 2024.
- VivoSim Labs, Inc. operating lease, payments for fiscal 2024 was $509.00K, a 18.37% increase from fiscal 2023.
- VivoSim Labs, Inc. operating lease, payments for fiscal 2023 was $430.00K, a 134.97% increase from fiscal 2022.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $138.00K 10-Q · filed 2026-08-12 | $275.00K derived: sum of 2 quarters · filed 2026-08-12 | $410.00K derived: sum of 3 quarters · filed 2026-08-12 | $544.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $272.00K derived: sum of 2 quarters · filed 2026-07-14 | $406.00K derived: sum of 3 quarters · filed 2026-07-14 | $539.00K 10-K · filed 2026-07-14 |
| 2025-12-31 | $135.00K 10-Q · filed 2026-02-11 | $269.00K derived: sum of 2 quarters · filed 2026-02-11 | $402.00K 10-Q · filed 2026-02-11 | $538.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | $134.00K 10-Q · filed 2025-11-06 | $267.00K 10-Q · filed 2025-11-06 | $403.00K derived: sum of 3 quarters · filed 2026-08-12 | $532.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $134.00K 10-Q · filed 2026-08-12 | $269.00K derived: sum of 2 quarters · filed 2026-08-12 | $398.00K derived: sum of 3 quarters · filed 2026-08-12 | $528.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $264.00K derived: sum of 2 quarters · filed 2026-07-14 | $394.00K derived: sum of 3 quarters · filed 2026-07-14 | $524.00K 10-K · filed 2026-07-14 |
| 2024-12-31 | $129.00K 10-Q · filed 2026-02-11 | $259.00K derived: sum of 2 quarters · filed 2026-02-11 | $389.00K 10-Q · filed 2026-02-11 | $521.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $130.00K 10-Q · filed 2025-11-06 | $260.00K 10-Q · filed 2025-11-06 | $392.00K derived: sum of 3 quarters · filed 2025-11-06 | $517.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $130.00K 10-Q · filed 2025-08-12 | $262.00K derived: sum of 2 quarters · filed 2025-08-12 | $387.00K derived: sum of 3 quarters · filed 2025-08-12 | $513.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-05 | $257.00K derived: sum of 2 quarters · filed 2025-06-05 | $383.00K derived: sum of 3 quarters · filed 2025-06-05 | $509.00K 10-K · filed 2025-06-05 |
| 2023-12-31 | $125.00K 10-Q · filed 2025-02-19 | $251.00K derived: sum of 2 quarters · filed 2025-02-19 | $377.00K 10-Q · filed 2025-02-19 | $503.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-09-30 | $126.00K 10-Q · filed 2024-11-08 | $252.00K 10-Q · filed 2024-11-08 | $378.00K derived: sum of 3 quarters · filed 2024-11-08 | $437.00K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $126.00K 10-Q · filed 2024-08-05 | $252.00K derived: sum of 2 quarters · filed 2024-08-05 | $311.00K derived: sum of 3 quarters · filed 2024-08-05 | $433.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-31 | $185.00K derived: sum of 2 quarters · filed 2024-05-31 | $307.00K derived: sum of 3 quarters · filed 2024-05-31 | $430.00K 10-K · filed 2024-05-31 |
| 2022-12-31 | $59.00K 10-Q · filed 2024-02-08 | $181.00K derived: sum of 2 quarters · filed 2024-02-08 | $304.00K 10-Q · filed 2024-02-08 | $486.00K derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | $122.00K 10-Q · filed 2023-11-09 | $245.00K 10-Q · filed 2023-11-09 | $427.00K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $122.00K 10-Q · filed 2023-08-10 | $305.00K derived: sum of 2 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $183.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-14 | $183.00K 10-K · filed 2023-07-14 | ||
| 2021-12-31 | $0.00 10-Q · filed 2022-02-14 | |||
| 2020-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-28 | $45.00K derived: sum of 2 quarters · filed 2020-05-28 | $314.00K derived: sum of 3 quarters · filed 2020-05-28 | $579.00K 10-K · filed 2020-05-28 |
| 2019-12-31 | $45.00K derived: 10-K 12 month − 3 quarters · filed 2020-05-28 | $314.00K derived: sum of 2 quarters · filed 2020-05-28 | $579.00K 10-Q · filed 2020-02-10 | |
| 2019-09-30 | $269.00K 10-Q · filed 2019-11-07 | $534.00K derived: sum of 2 quarters · filed 2019-11-07 | ||
| 2019-06-30 | $265.00K 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |